SOCS1 and arthritic joint disease: In 2022, a patient with heterozygous SOCS1-deletion and severe enthesitis-related arthritis showed significant improvement upon tofacitinib treatment, even stabilizing immunocytopenia (ITP) that was poorly controlled with conventional immunosuppression (32).